Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Jan 25, 2023

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Jan 9, 2023

Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis

Dec 6, 2022

Ocuphire to Present at Five Upcoming Investor/Industry Conferences

Nov 21, 2022

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

Nov 7, 2022

Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

Nov 4, 2022

Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

Nov 2, 2022

Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

Oct 24, 2022

Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

Oct 7, 2022

Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease

Oct 6, 2022